11/26/2024
Anapharm Bioanalytics Recognized as an Innovative SME
We are thrilled to announce that Anapharm Bioanalytics has recently been officially recognized as an Innovative SME (PYME Innovadora) by the Spanish Ministry of Science and Innovation.
This accreditation highlights our ongoing efforts to advance bioanalytical services through continuous investment in research and development (R&D) and cutting-edge innovation. As a client-focused bioanalytical contract research organization (CRO), we proudly support biotech and pharmaceutical development accross all stages—from early preclinical studies to clinical research.
Being accredited as an Innovative SME reflects not only our commitment to staying at the forefront of bioanalytics but also our ability to adapt to the evolving needs of the biotech and pharmaceutical industries. This recognition further validates our dedication to delivering high-quality, efficient, and reliable services that accelerate drug development timelines.
At Anapharm Bioanalytics, innovation is at the core of everything we do. From offering state-of-the-art bioanalytical services to accelerating drug development timelines, we are proud to contribute to the development of life-saving therapies.
As your trusted partner, we are here to help you navigate the complexities of drug development and bring new treatments to market faster.
Join us on our journey of advancing global healthcare through innovative bioanalytical solutions. Contact us today to learn how our expertise can support your drug development needs.
MORE NEWS
Anapharm Bioanalytics Brazilian ANVISA Certificate Renewal
Anapharm Bioanalytics is proud to announce that it has recently renewed its ANVISA (Brazil) certification which is now valid until February 26th, 2026.
Anapharm Bioanalytics Secures Funding from Eurostars and CDTI for Innovative Project on Therapy and Diagnosis of Ewing Sarcoma
Barcelona, April 18th, 2023 – Anapharm Bioanalytics, a leading bioanalytical contract research organization (CRO), is delighted to announce the successful acquisition of funding from the Eurostars-3 joint program, with co-funding from CDTI (Centre for Industrial Technological Development) and the European Union’s Horizon Europe Research and Innovation Framework. This funding marks a significant milestone for the groundbreaking project, a collaborative effort between Anapharm Bioanalytics, iCellate Medical, and Aptadel Therapeutics.
Challenges in the Development of a Method for the Detection of Anti-PEGylated-aptamer Antibodies
Immunogenicity assays capable of properly determining the presence of anti-drug antibodies (ADA) and anti-PEG antibodies have been recognized of great importance due to the fact that pre-existing anti-PEG antibodies could have an impact on the efficacy of a drug coupled to polyethylene glycol (PEG).